Forschungsschwerpunkte: Pieris’ strategy is to ensure broad exploitation of Anticalins as differentiated drug candidates in areas of high-unmet medical need. The Company is achieving this by pursuing a three-fold licensing and drug development model: - Fully partnered Anticalins at the discovery stage via R&D partnerships, where the partner funds all development costs. Our collaborations with Daiichi-Sankyo and Sanofi Group are examples of these types of partnerships. - Fully proprietary Anticalin drug candidates, where Pieris funds all development costs. PRS-080 (hepcidin antagonist to treat anemia), PRS-060 (inhaled IL4Ra antagonist to treat asthma) and our 300-Series multispecifics (immuno-oncology) are examples of these types of programs. - Hybrid arrangements, where Pieris advances Anticalin drug candidates under a co-development license, where Pieris invests in the discovery stage and the partner invests from preclinical through at least early clinical development. Our collaborations with Zydus Cadila and Stelis Biopharma are examples of this approach.